Intravitreal faricimab (vabysmo) in neovascular age-related macular degeneration (namd) and diabetic macular edema (dme): Structured evidence review

Background

Anti-VEGF intravitreal therapy has transformed the treatment of neovascular age-related macular degeneration and diabetic macular edema; however, issues like treatment burden and incomplete anatomic responses persist. Faricimab (Vabysmo) is a humanized bispecific antibody that inhibits both VEGF-A and stabilizes vessels, addressing these challenges through its dual action.